Drug profile

The FDA adverse-event record for Panacur

89 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Panacur. See the species affected, top reactions, and outcomes below.

89
adverse-event reports
5.6%
death-coded share
Dog
most-reported species
27
Lack of efficacy (endoparasite) - hookworm - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
89
Total Reports
5
Deaths Reported
5.6%
Death Rate

Active Ingredients

Panacur

Administration Routes

OralUnknownOther

Species Affected

Dog 72
Cat 9
Horse 4
Cattle 2
Rabbit 1
Deer 1

Most Affected Breeds

Retriever - Labrador 9
Crossbred Canine/dog 7
Domestic Shorthair 6
Greyhound 5
Retriever - Golden 5
Beagle 4
Terrier - Bull - American Pit 3
Mountain Dog - Bernese 3
Schnauzer - Miniature 3
Shepherd Dog - Australian 3

Most Reported Reactions

Lack of efficacy (endoparasite) - hookworm 27
Lack of efficacy (endoparasite) - roundworm NOS 17
Diarrhoea 10
Vomiting 10
Leucocytosis NOS 7
Lethargy (see also Central nervous system depression in Neurological) 7
Other abnormal test result NOS 5
Decreased haematocrit 5
Bloody diarrhoea 4
Lack of efficacy (endoparasite) - tapeworm 4
Increased band neutrophilia 4
Lack of efficacy (endoparasite) - strongylids 4

Outcome Breakdown

Ongoing
52 (58.4%)
Recovered/Normal
19 (21.3%)
Outcome Unknown
13 (14.6%)
Euthanized
3 (3.4%)
Died
2 (2.2%)

Panacur Adverse Event Insights

89 reports name Panacur; 5 recorded a death outcome (5.6% of reported events, not a population-level mortality rate). Active ingredient: Panacur. Administration routes: Oral, Unknown, Other.

By species: Dog (72 reports), Cat (9 reports), Horse (4 reports). By breed: Retriever - Labrador (9), Crossbred Canine/dog (7), Domestic Shorthair (6).

Leading clinical signs: Lack of efficacy (endoparasite) - hookworm (27), Lack of efficacy (endoparasite) - roundworm NOS (17), Diarrhoea (10), Vomiting (10). Outcome, 89 coded reports: Ongoing leads at 58.4%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.